Healthcare Business News

MANCHESTER, CT–(Marketwire – December 9, 2010) – Manchester Manor Health Care Center has been recognized as a 2010 recipient of the National Quality Award at the level of Gold – Excellence in Quality presented by the American Health Care Association/National Centers for Assisted Living (AHCA/NCAL), a Washington D.C. based trade organization with approximately 11,000 nursing facility members nationwide. Manchester Manor is the only 2010 recipient of this distinguished national award. Over the 15 years of the Quality Award program, only 4 companies, owning 10 facilities, have ever received an award at this level. The award was formally presented to Manchester Manor during AHCA’s 61^st Annual Convention and Exposition, October 10-13, 2010 in Long Beach, CA.

“The staff and leadership of Manchester Manor Health Care Center have demonstrated that they can sustain a high level of performance across a broad spectrum of services, and have set themselves apart as a health care organization of the highest distinction,” stated Bruce Yarwood, President and CEO of AHCA. “We applaud this outstanding achievement that honors their commitment to a rigorous journey of continuous improvement.”

Implemented by AHCA/NCAL in 1996, the National Quality Award Program is based on the core values and criteria of the Malcolm Baldrige National Quality Award Program. It provides a pathway for providers of long term and post-acute care services to journey towards performance excellence. Applicants for the prestigious Gold – Excellence in Quality award demonstrate by approach, deployment and consistency of results that they are achieving high levels of performance in health care, customer satisfaction, market, workforce, process and leadership outcomes over time. At the Gold level, applicants must successfully address the Malcolm Baldrige Program’s Health Care Criteria for Performance Excellence. Gold applications are reviewed by teams of Master Examiners with extensive qualifications and special training to qualify as judges. A ten member Board of Overseers provides oversight of the award program.

“No one knows better than the staff at Manchester Manor that their quality journey never ends, but this award level is a significant achievement,” stated Bernie Dana, Chair, AHCA/NCAL National Quality Award Board of Overseers. “Clearly Manchester Manor is one of the very best long term care providers in the entire nation.”

Manchester Manor Health Care Center previously received the Silver – Achievement in Quality Award (2008) and the Bronze – Commitment to Quality Award (2007).

Click here to see all recent news from this company

RICHARDSON, TX–(Marketwire – December 8, 2010) – KBM Group, the global leader in knowledge-based marketing solutions, has agreed to acquire Marketing Direct, Inc. (MDI), the leading provider of agency services to the healthcare industry. MDI is an integrated marketing services company with expertise in strategy, design and execution of marketing campaigns, from go-to-market strategies and sales-lead conversion to media placement, primarily for the healthcare industry. The acquisition strengthens and broadens KBM Group’s existing products and services for the healthcare market, augmenting the company’s core capabilities with a wide array of agency services such as creative and media placement, including digital media channels. Based in St. Louis, MO, MDI is a privately held company. Financial terms of the deal are not being disclosed, and the acquisition is subject to regulatory and shareholder approvals.

Founded in 1997, MDI has been ranked one of America’s fastest-growing private companies by Inc. Magazine in its annual Inc. 5000 survey for 2008, 2009 and 2010. The company’s growth has been driven by providing direct and interactive marketing services primarily to the healthcare industry, but the company has experience in retail and financial services as well. MDI’s capabilities span marketing services end-to-end, including: consulting services, developing and optimizing direct market channels, facilitating the sales process through sales force automation, determining the best mix of online and offline media, performing analytics and testing to ensure results, developing creative campaigns from messages to branding, optimizing websites and online strategies, and media placement and execution. Providing these multichannel marketing services to targeted industries has given MDI industry-specific expertise that has allowed it to help its clients acquire millions of customers and engage them to improve healthcare outcomes.

With the combined strength of the acquisition, KBM Group is also officially announcing the launch of KBM Group: Health Services, a new business practice focused on improving how companies across the healthcare continuum engage with consumers and healthcare professionals. KBM Group: Health Services will immediately intensify its focus on helping organizations within the healthcare ecosystem create more meaningful engagements with consumers for the ultimate goal of improving healthcare outcomes while reducing the overall cost of healthcare services. Dennis Barnes, Jr., President & CEO of MDI, will become President, KBM Group: Health Services. The new unit will remain part of Enterprise Services within KBM Group.

“While KBM Group and MDI have been recognized and established leaders within healthcare for several years now, current and impending changes to healthcare require a more holistic approach to multi-channel engagement if we are to substantially reduce costs while improving outcomes,” says Dennis Kooker, KBM Group’s President & COO for Enterprise Services. “Combining KBM Group’s industry standards for data, analytics, and database services delivered through its Consumer Healthcare Engagement Platform (CHEP) with MDI’s expertise in blending creative content and program design with analytics was an obvious combination. MDI has also invested heavily within innovative digital channels that mark the future of consumer engagement. The fundamental beliefs of our organizations and how to serve the healthcare ecosystem are very much aligned.”

Dennis Barnes, President & CEO of MDI, says, “We look forward to contributing our successful record of growth and healthcare expertise to KBM Group, and to integrating our capabilities with KBM Group’s superb data and analytics capability. As an agency specializing in healthcare, we are impressed with the level of healthcare subject matter expertise and the vision that KBM Group has created for the healthcare ecosystem. I am thrilled to have the opportunity to lead an organization with the combined resources and capabilities that KBM Group Health will possess; not to mention how exciting it is to be able to prove our more fundamental goal of driving down the cost of healthcare in this country without needing to make villains out of the healthcare providers.” 

New York-based mergers & acquisition firm AdMedia Partners acted as exclusive financial advisor to MDI in the transaction (www.admediapartners.com). For information about MDI and its transition to KBM Group: Health Services, go to www.marketingdirect.com.

About KBM Group
KBM Group is the global leader in knowledge-based marketing solutions. Expert in both digital and traditional direct marketing, KBM Group helps companies manage, analyze and optimize marketing data to engage more effectively with their customers and prospects. KBM Group’s integrated, world-class solutions include strategic consulting, digital services, database services, analytics, marketing management, response services, data and marketing outsourcing. The company has 16 offices in nine countries serving global, enterprise and B2B2C-focused companies. KBM Group’s parent company, Wunderman is part of Young & Rubicam Brands and a member of WPP (NASDAQ: WPPGY). www.kbmg.com.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – December 7, 2010) – The Southeastern Medical Device Association’s (SEMDA) 5^th annual conference will take place on March 29-30, 2011, adding a half day to the popular medical device event. Recognized as the premier gathering for the Southeast medical device industry, the conference balances presentations by medical device companies to investors with educational programs and networking opportunities.

Specifically designed to meet the needs of medical device industry professionals, the expanded format will allow additional time for educational and panel presentations, as well as one-on-one meetings.

Another addition for 2011 is a Gala Dinner, which will be held on March 29 at the Georgia Tech Hotel and Conference Center. The annual SpotLight Awards, which recognize individuals and companies that have made substantial contributions to the growth of the Southeastern medical device industry, will be presented during the dinner.

This year’s conference will be held at the Georgia Tech Global Learning Center, a midtown Atlanta conference facility that offers more room for presentations and meetings, complemented by state-of-the-art technology capabilities.

Other highlights will include:

• Keynote presentations from industry leaders
• Presentations from some of the region’s top existing and emerging medical device companies
• Workshops on a variety of topics including critical business issues affecting those within the industry
• Panel discussions by VCs and business development professionals, as well as a CEO Roundtable
• Numerous industry networking opportunities

For more information about the conference, sponsorship opportunities, presenting company application or registration, visit www.semdaconference.com.

About SEMDA
The Southeastern Medical Device Association (SEMDA) is a non-profit association that supports and promotes the medical device companies in the Southeast. Created in 2004, the association provides a unique resource and networking opportunity for medical device companies, entrepreneurs, inventors, physicians, and investors interested in accelerating the growth of the medical device industry in the Southeast. For more information, visit www.semda.net

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – December 7, 2010) – Allied Healthcare International Inc. (NASDAQ: AHCI), a leading provider of flexible healthcare staffing services in the
United Kingdom, today issued financial results for its fiscal 2010 fourth
quarter and year-ended September 30, 2010.

To provide investors with a better understanding of the Company’s
performance and because of fluctuations in foreign exchange rates, Allied
is discussing its revenues, gross profit, selling, general & administrative
(SG&A) expenses and operating income at constant exchange rates, which are
calculated using the comparable prior period weighted average exchange
rates. In addition, as the Company’s revenues and gross profit from our
principal operations are denominated in pounds sterling but reported in
United States dollars, an analysis, which is contained in the Historical
Revenues and Gross Profit table at the end of this press release, is
included of the last eight quarters’ revenues and gross profit in pounds
sterling to enable investors to fully understand the underlying trends over
these periods without the effects of currency exchange rates.

Fiscal Fourth Quarter Results

              Three Months Ended
                 September 30,         Three Months Ended September 30,
            -----------------------  -------------------------------------
                                %                                     %
              2010     2009   Change   2010     %      2009     %   Change
            -------- -------- ------ -------  -----  -------- ----- ------
                    Revenues                     Gross Profit
            ------------------------ -------------------------------------

(Amounts in
 thousands)
Homecare    $64,244  $ 58,388  10.0% $19,934   31.0% $ 17,893  30.6%  11.4%
Nursing
 Homes        4,998     6,568 -23.9%   1,641   32.8%    2,070  31.5% -20.7%
Hospitals     5,120     4,889   4.7%   1,326   25.9%    1,233  25.2%   7.5%
            -------  -------- -----  -------         --------        -----
Total, at
 constant
 exchange
 rates       74,362    69,845   6.5%  22,901   30.8%   21,196  30.3%   8.0%
Effect of
 foreign
 exchange    (3,945)        -  -5.6%  (1,189)               -         -5.6%
            -------  -------- -----  -------         --------        -----
Total, as
 reported   $70,417  $ 69,845   0.8% $21,712         $ 21,196          2.4%
            =======  ======== =====  -------         --------        -----


                                                     SG&A
                                     -------------------------------------
SG&A, at
 constant
 exchange
 rates &
 excluding
 acquisition
 costs                               $19,033         $ 17,010         11.9%
Acquisition
 costs, at
 constant
 exchange
 rates                                   157                -          0.9%
                                     -------         --------        -----
SG&A, at
 constant
 exchange
 rates                                19,190           17,010         12.8%
Effect of
 foreign
 exchange                               (946)               -         -5.6%
                                     -------         --------        -----
Total SG&A,
 as reported                         $18,244         $ 17,010          7.3%
                                     -------         --------        -----


                                               Operating Income
                                     -------------------------------------
Operating
 income, at
 constant
 exchange
 rates &
 excluding
 acquisition
 cost                                $ 3,868         $  4,186         -7.6%
Acquisition
 costs, at
 constant
 exchange
 rates                                  (157)               -         -3.8%
                                     -------         --------        -----
Operating
 income, at
 constant
 exchange
 rates                                 3,711            4,186        -11.3%
Effect of
 foreign
 exchange                               (243)               -         -5.8%
                                     -------         --------        -----
Operating
 income, as
 reported                            $ 3,468         $  4,186        -17.2%
                                     =======         ========        =====


                                       Net Income Attributable to Allied
                                     -------------------------------------
                                              Basic           Basic
                                               and             and
                                             Diluted         Diluted
                                               EPS             EPS
                                     -------------------------------------
Income from continuing
 operations attributable
 to Allied, excluding
 acquisition costs                   $ 2,858  $0.07  $  2,937 $0.07
Acquisition Costs                       (146) -0.01         -     -
                                     -------  -----  -------- -----
Income from continuing
 operations attributable
 to Allied                           $ 2,712  $0.06  $  2,937 $0.07
                                     =======  =====  ======== =====

For the fourth quarter of fiscal 2010, total revenue increased 6.5%, to
$74.4 million, compared with $69.8 million reported during the same period
in fiscal 2009. Allied’s Homecare revenue grew 10.0% to $64.2 million. The
acquisition completed in our third fiscal quarter contributed 7.5%, or $4.4
million, to the increase in Homecare revenues. Nursing Homes revenue
declined 23.9% to $5.0 million and Hospitals revenue increased 4.7% to $5.1
million. After the unfavorable impact of currency exchange of $3.9 million,
revenue increased 0.8% year over year to the reported $70.4 million.

Total gross profit for the fourth fiscal quarter increased 8.0% to $22.9
million, from $21.2 million for the comparable quarter in fiscal 2009.
Homecare gross profit grew 11.4% to $19.9 million. The acquisition
completed in our third fiscal quarter contributed 7.6%, or $1.4 million, to
the increase in Homecare gross profit. Nursing Homes gross profit declined
20.7% to $1.7 million and Hospitals gross profit increased 7.5% to $1.3
million. Gross profit as a percentage of revenue was 30.8%, compared with
30.3% for the comparable prior-year period. Foreign exchange decreased
gross profit by $1.2 million to the reported $21.7 million for the 2010
fourth fiscal quarter.

SG&A, excluding acquisition costs, for the fourth fiscal quarter was $19.0
million (25.6% of revenues), an increase of 11.9%, from $17.0 million
(24.4% of revenues) reported last year. The acquisition completed in our
third fiscal quarter contributed 6.4%, or $1.0 million, to the increase in
SG&A. The Company also incurred acquisition costs of $0.1 million.
Foreign exchange decreased costs by $0.9 million to the reported $18.2
million for the 2010 fourth fiscal quarter.

Operating income, before acquisition costs, for the fourth quarter of
fiscal 2010 decreased by 7.6% to $3.9 million from $4.2 million a year ago.
Acquisition costs decreased operating income by $0.1 million. Foreign
exchange decreased operating income by $0.3 million to the reported $3.5
million for the 2010 fourth fiscal quarter.

Income from continuing operations attributable to Allied, excluding
acquisition costs, for the fourth quarter of fiscal 2010 was $2.9 million,
or $0.07 per diluted share. Income from continuing operations attributable
to Allied for the fourth quarter of fiscal 2010 was $2.7 million, or $0.06
per diluted share, compared with $2.9 million, $0.07 per diluted share,
reported during the 2009 fourth fiscal quarter.

Fiscal 2010 Full Year Results

            Year Ended September 30,       Year Ended September 30,
            ------------------------ -------------------------------------
                                %                                     %
              2010     2009   Change   2010     %      2009     %   Change
            -------- -------- ------ -------  -----  -------- ----- ------
                    Revenue                      Gross Profit
            ------------------------ -------------------------------------

(Amounts in
 thousands)
Homecare    $231,718 $203,885  13.7% $71,314   30.8% $ 63,176  31.0%  12.9%
Nursing
 Homes        18,469   25,863 -28.6%   5,971   32.3%    8,097  31.3% -26.3%
Hospitals     19,571   20,062  -2.4%   4,618   23.6%    5,075  25.3%  -9.0%
            -------- -------- -----  -------         --------       ------
Total, at
 constant
 exchange
 rates       269,758  249,810   8.0%  81,903   30.4%   76,348  30.6%   7.3%
Effect of
 foreign
 exchange      1,321        -   0.5%     402                -          0.5%
            -------- -------- -----  -------         --------       ------
Total, as
 reported   $271,079 $249,810   8.5% $82,305         $ 76,348          7.8%
            ======== ======== =====  -------         --------       ------


                                                    SG&A
                                     -------------------------------------
SG&A, at
 constant
 exchange
 rates &
 excluding
 acquisition
 costs                               $67,776         $ 63,234          7.2%
Acquisition
 costs, at
 constant
 exchange
 rates                                   752                -          1.2%
                                     -------         --------        -----
SG&A, at
 constant
 exchange
 rates                                68,528           63,234          8.4%
Effect of
 foreign
 exchange                                318                -          0.5%
                                     -------         --------        -----
Total SG&A,
 as reported                         $68,846         $ 63,234          8.9%
                                     -------         --------        -----


                                                 Operating Income
                                     -------------------------------------
Operating
 income, at
 constant
 exchange
 rates &
 excluding
 acquisition
 cost                                $14,127         $ 13,114          7.7%
Acquisition
 costs, at
 constant
 exchange
 rates                                  (752)               -         -5.7%
                                     -------         --------        -----
Operating
 income, at
 constant
 exchange
 rates                                13,375           13,114          2.0%
Effect of
 foreign
 exchange                                 84                -          0.6%
                                     -------         --------        -----
Operating
 income, as
 reported                            $13,459         $ 13,114          2.6%
                                     =======         ========        =====


                                       Net Income Attributable to Allied
                                     -------------------------------------
                                              Basic            Basic
                                               and              and
                                             Diluted          Diluted
                                               EPS              EPS
                                     -------------------------------------
Income from continuing
 operations attributable to
 Allied, excluding
 acquisition cost                    $10,624  $0.24  $  9,936 $0.22

Acquisition costs                       (756) -0.02         -     -
                                     -------  -----  -------- -----
Income from continuing
 operations attributable to
 Allied                              $ 9,868  $0.22  $  9,936 $0.22
                                     =======  =====  ======== =====

For the year ended September 30, 2010 total revenue increased 8.0%, to
$269.8 million, compared with $249.8 million for the same period in fiscal
2009. Allied’s Homecare revenue grew 13.7% to $231.7 million. The
acquisition completed in the third quarter of fiscal 2010 contributed 3.2%,
or $6.5 million, to the increase in Homecare revenues. Nursing Homes
revenue declined 28.6% to $18.5 million and Hospitals revenue declined 2.4%
to $19.6 million. After the favorable impact of currency exchange of $1.3
million, revenue increased 8.5% year over year to the reported $271.1
million for fiscal 2010.

Total gross profit for the year ended September 30, 2010 increased 7.3% to
$81.9 million, from $76.3 million for the comparable period in fiscal 2009.
Homecare gross profit grew 12.9% to $71.3 million. The acquisition
completed in our third fiscal quarter contributed 3.1%, or $2.0 million, to
the increase in Homecare gross profit. Nursing Homes gross profit declined
26.3% to $6.0 million and Hospitals gross profit declined 9.0% to $4.6
million. Gross profit as a percentage of revenue was 30.4%, compared with
30.6% for the comparable prior-year period. Foreign exchange increased
gross profit by $0.4 million to the reported $82.3 million for fiscal 2010.

SG&A, excluding acquisition costs, for the year ended September 30, 2010
was $67.8 million (25.1% of revenues), an increase of 7.2%, from $63.2
million (25.3% of revenues) reported last year. The acquisition completed
in our third fiscal quarter contributed 2.4%, or $1.5 million, to the
increase in SG&A. We also incurred acquisition costs of $0.7 million.
Foreign exchange increased costs by $0.3 million to the reported $68.8
million for fiscal 2010.

Operating income, before acquisition costs, for the year ended September
30, 2010 increased by 7.7% to $14.1 million from $13.1 million a year ago.
Acquisition costs decreased operating income by $0.7 million. Foreign
exchange increased operating income by $0.1 million to the reported $13.5
million for fiscal 2010.

Income from continuing operations attributable to Allied, excluding
acquisition costs, for the year ended September 30, 2010 was $10.6 million,
or $0.24 per diluted share. Income from continuing operations attributable
to Allied for the year ended September 30, 2010 was $9.9 million, or $0.22
per diluted share, compared with $9.9 million, $0.22 per diluted share,
reported during fiscal 2009.

At September 30, 2010 and September 30, 2009, Allied cash balance was $39.0
million (£24.7 million) and $35.3 million (£22.2 million), respectively,
represent an underlying increase in the cash balance of $3.7 million (£2.5
million).

For the year ended September 30, 2010, depreciation and amortization was
$4.4 million (£2.8 million), capital expenditures were $2.8 million (£1.8
million). Days Sales Outstanding was 26 days at September 30, 2010 (43 days
including unbilled account receivables), and 25 days at September 30, 2009
(40 days including unbilled account receivables).

Management Discussion

Sandy Young, Chief Executive Officer of Allied, commented, “Allied’s
financial performance during the fourth quarter reflects tightening in the
U.K. government’s spending and challenging macroeconomic factors. The
acquisition of Homecare business in Ireland contributed $4.4 million to
Allied’s top line during the quarter, resulting in 10% growth of our
Homecare revenue compared to the fourth quarter a year ago. Excluding the
acquisition, our Homecare revenue grew 2.5% year over year, with an 11.5%
increase in continuing care.

“In order to reduce the U.K. government’s fiscal deficit, following its
Comprehensive Spending Review, HM Treasury announced in October 2010 its
plans to achieve a significant reduction in public spending. While the U.K.
government has stated that it will increase spending in the National Health
Service over the next four years to support healthcare, we note the
increase will be partially offset as the NHS have increased obligations and
cost of treatments going forward due to the growing population and demand
for better healthcare. However, the Comprehensive Spending Review will
also allocate £2 billion a year of additional funding by 2014-15 to support
social care. Combined with a program of reform and efficiency savings,
such as greater use of personal budgets, the U.K. government believes this
should mean local authorities should be able to improve outcomes and should
not need to reduce eligibility for services.

“The Comprehensive Spending Review also announced significant cuts in
funding to local authorities, the main providers of social care, and other
public bodies, which are a key source of revenue to Allied. Individual
local authorities will decide which of their back office costs and front
line services to allocate savings to.

“Based on the current and anticipated changes in the U.K. government’s
policies, we believe that it is possible that demand will be flat on a
consecutive basis for the near term. However, due to Allied’s favorable
position in the industry, strong reputation and innovative business
approach, we expect to return to growth in the mid-term.

“Allied is in a good position to benefit from joint commissioning of health
and social care. For example:

-- Within our homecare revenue, we have over $159 million (£102 million) in
   social care revenue, $57.7 million (£37 million) in continuing care
   revenue and $13.3 million (£8.5 million) in learning disability revenue;
-- We are introducing new Primary Care Trust services this year. They will
   include our night roaming service, our end of life services and other
   specialist health services;
-- We are winning extra care contracts, a potentially new revenue stream;
-- We are looking at new homecare solutions, including
   Telecare/Telehealth; and
-- We are extending the boundaries of the care and supported living we
   provide to include children's services and services for drug and alcohol
   abuse.  Some of these require rental housing to be part of the package.

“Although we anticipate that there will be continuing tension in spending,
we believe that councils and PCTs are likely to:

-- Outsource more than they do at present, particularly in Scotland, Wales
   and Ireland;
-- Have the ability to get incremental savings by directing greater volumes
   to providers of scale like Allied;
-- Keep individuals out of hospital and in their own homes;
-- Favor lower cost homecare over more  expensive residential care;
-- Pursue new and quite entrepreneurial services around the end of life
   pathway; and
-- Still need to provide for the increasing numbers of elderly each year.

“So today, Allied can claim to be one of the leading providers of health
and social care in the U.K., and we continue to expand our market
footprint. During the fourth quarter and in subsequent months we won a
number of domiciliary care framework contracts, the two largest being:

-- East Sussex County Council -- Up to 2,000 hours per week for four years,
   which commenced November 2010.
-- Cardiff City Council -- Up to 2,000 hours per week for three years,
   commencing April 2011.

“In addition we have won a community homecare contract with Leeds City
Council and NHS, and a contract for nursing supplied with Welsh Health
Supply. We have also seen a number of positive wins in continuing care from
framework agreements, including Doncaster and an additional opportunity in
Sheffield.

“In a consistent pursuit of improving and expanding our value proposition,
we continued to make investments in our operational infrastructure. To
date, 55 of our branches are live on Coldharbour, and the software rollout
is continuing according to plan. Our customer complaints and risk
management system, which was built in house, is currently under testing and
is planned to go live at the beginning of calendar 2011. Additionally, we
are actively working on several other projects, such as call monitoring,
carer retention and the centralization of our on-call out of hours service.
We also piloted our recruitment screening and compliance department project
in Wales and have received very positive feedback. Our recruitment pipeline
tracker is undergoing design changes for full rollout to the business in
the near future.

“In summary, Allied is well positioned to capitalize on the growing elderly
population, shift from residential to homecare services and the move
towards joint commissioning of health and social care,” concluded Mr.
Young.

Dr. Jeffrey Peris, Chairman of Allied, commented, “The Board remains
confident in the opportunities for growth through management actions on
innovative initiatives. Based on our identified strategies for growth
being successfully implemented, our financial track record over the last
few years, our focus and results in improving operating efficiencies, and
the recruitment and retention of talented people — we continue to strive
to enhance shareholder value.”

Conference Call Information: December 7, 2010 at 10:00 AM Eastern Time /
3:00 PM UK Time

Allied will host a call and webcast today at 10:00 AM Eastern Time / 3:00
PM UK Time, to discuss its financial results. To join the call, please dial
(877) 407-8031 for domestic participants and (201) 689-8031 for
international participants. Participants may also access a live webcast of
the conference call through the “Investors” section of Allied Healthcare’s
Website: www.alliedhealthcare.com. A telephone replay will be available for
two weeks following the call by dialing (877) 660-6853 for domestic
participants and (201) 612-7415 for international participants. When
prompted, please enter account number 286 and conference ID number 360782.
A webcast replay will also be available and archived on the Company’s
website for ninety days.

Reconciliation of GAAP and Non-GAAP Data

In addition to disclosing results of operations that are determined in
accordance with generally accepted accounting principles (“GAAP”), this
press release also discloses non-GAAP results of operations that exclude or
include certain charges. These non-GAAP measures adjust for foreign
exchange effects and acquisition costs. Management believes that the
presentation of these non-GAAP measures provides useful information to
investors regarding the Company’s results of operations, as these non-GAAP
measures allow investors to better evaluate ongoing business performance.
Investors should consider non-GAAP measures in addition to, and not as a
substitute for, financial measures prepared in accordance with GAAP. A
reconciliation of the non-GAAP measures disclosed in this press release
with the most comparable GAAP measures are included in the financial tables
included in this press release.

ABOUT ALLIED HEALTHCARE INTERNATIONAL INC.

Allied Healthcare International Inc. is a leading provider of flexible
healthcare staffing services in the United Kingdom. Allied operates a
community-based network of approximately 115 branches with the capacity to
provide carers (known as home health aides in the U.S.), nurses, and
specialized medical personnel to locations covering approximately 90% of
the U.K. population. Allied meets the needs of private patients, community
care, nursing and care homes, and hospitals. For more news and information
please visit: www.alliedhealthcare.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release may be forward-looking
statements. These forward-looking statements are based on current
expectations and projections about future events. Actual results could
differ materially from those discussed in, or implied by, these
forward-looking statements. Factors that could cause actual results to
differ from those implied by the forward-looking statements include:
general economic and market conditions; the effect of the change in the
U.K. government and the impact of proposed changes in recent policy making
related to health and social care that may reduce revenue and
profitability; the impact of the HM Treasury Comprehensive Spending Review
2010 setting out the U.K. government’s plans to reduce spending; Allied’s
ability to continue to recruit and retain flexible healthcare staff;
Allied’s ability to enter into contracts with local government social
services departments, NHS Trusts, hospitals, other healthcare facility
clients and private clients on terms attractive to Allied; the general
level of demand and spending for healthcare and social care; dependence on
the proper functioning of Allied’s information systems; the effect of
existing or future government regulation of the healthcare and social care
industry, and Allied’s ability to comply with these regulations; the impact
of medical malpractice and other claims asserted against Allied; the effect
of regulatory change that may apply to Allied and that may increase costs
and reduce revenues and profitability; the effect of existing or future
government regulation in relation to employment and agency workers’ rights
and benefits, including changes to National Insurance rates and pension
provision; Allied’s ability to use net operating loss carry forwards to
offset net income; the effect that fluctuations in foreign currency
exchange rates may have on our dollar-denominated results of operations;
and the impairment of goodwill, of which Allied has a substantial amount on
the balance sheet, may have the effect of decreasing earnings or increasing
losses. Other factors that could cause actual results to differ from those
implied by the
forward-looking statements in this press release include those described in
Allied’s most recently filed SEC documents, such as its most recent annual
report on Form 10-K, all quarterly reports on Form 10-Q and any current
reports on Form 8-K filed since the date of the last Form 10-K. Allied
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, or
otherwise.

ALLIED HEALTHCARE INTERNATIONAL INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)


                                         Year Ended  Year Ended  Year Ended
                                         September   September   September
                                          30, 2010    30, 2009    30, 2008
                                         ----------  ----------  ---------
Revenues:
    Net patient services                 $  271,079  $  249,810  $ 298,577
                                         ----------  ----------  ---------

Cost of revenues:
    Patient services                        188,774     173,462    208,192
                                         ----------  ----------  ---------

          Gross profit                       82,305      76,348     90,385

Selling, general and administrative
 expenses                                    68,846      63,234     77,655
                                         ----------  ----------  ---------

          Operating income                   13,459      13,114     12,730

Interest income                                 361         537        935
Interest expense                                (30)       (110)      (542)
Foreign exchange loss                          (210)       (197)      (586)
                                         ----------  ----------  ---------

          Income before income taxes
           and discontinued operations       13,580      13,344     12,537

Provision for income taxes                    3,524       3,408      3,751
                                         ----------  ----------  ---------

          Income from continuing
           operations                        10,056       9,936      8,786
                                         ----------  ----------  ---------

Discontinued operations:
Income from discontinued operations,
 net of taxes                                     -         367          -
                                         ----------  ----------  ---------

Net income                                   10,056      10,303      8,786

Less:  Net income attributable to
 noncontrolling interest                       (188)          -          -
                                         ----------  ----------  ---------

Net income attributable to Allied
 Healthcare International Inc.           $    9,868  $   10,303  $   8,786
                                         ==========  ==========  =========

Amounts attributable to Allied
 Healthcare International Inc.:
          Income from continuing
           operations, net of tax        $    9,868  $    9,936  $   8,786
          Discontinued operations,
           net of tax                             -         367          -
                                         ----------  ----------  ---------
          Net income                     $    9,868  $   10,303  $   8,786
                                         ==========  ==========  =========

Basic earnings per share - attributable
 to Allied Healthcare International Inc.
 common shareholders
          Income from continuing
           operations                    $     0.22  $     0.22  $    0.20
          Income from discontinued
           operations                             -        0.01          -
                                         ----------  ----------  ---------
Net income attributable to Allied
 Healthcare International Inc. common
 shareholders                            $     0.22  $     0.23  $    0.20
                                         ==========  ==========  =========

Diluted earnings per share - attributable
 to Allied Healthcare International Inc.
 common shareholders
          Income from continuing
           operations                    $     0.22  $     0.22  $    0.19
          Income from discontinued
           operations                             -        0.01          -
                                         ----------  ----------  ---------
Net income attributable to Allied
 Healthcare International Inc. common
 shareholders                            $     0.22  $     0.23  $    0.19
                                         ==========  ==========  =========

Weighted average number of common
 shares outstanding:
          Basic                              44,796      44,986     44,986
                                         ==========  ==========  =========
          Diluted                            45,009      45,011     45,078
                                         ==========  ==========  =========





ALLIED HEALTHCARE INTERNATIONAL INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)

                                              September 30,  September 30,
                                                  2010           2009
                                              -------------  -------------
                          ASSETS

Current assets:
  Cash and cash equivalents                   $      39,031  $      35,273
  Accounts receivable, less allowance for
   doubtful accounts of $732 and $839,
   respectively                                      20,092         19,594
  Unbilled accounts receivable                       13,393         11,572
  Deferred income taxes                                 552            389
  Prepaid expenses and other assets                   1,943          1,188
                                              -------------  -------------
         Total current assets                        75,011         68,016

Property and equipment, net                           8,924          7,756
Goodwill                                            102,945         95,649
Other intangible assets, net                          3,501          1,646
                                              -------------  -------------
         Total assets                         $     190,381  $     173,067
                                              =============  =============

       LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Accounts payable                            $       1,581  $       1,186
  Current maturities of debt and capital leases         614              -
  Accrued expenses, inclusive of payroll and
   related expenses                                  25,897         24,304
  Taxes payable                                       2,310            201
                                              -------------  -------------
         Total current liabilities                   30,402         25,691

Long-term debt and capital leases, net of
 current maturities                                     389              -
Deferred income taxes                                 1,534            103
Other long-term liabilities                             308              -
                                              -------------  -------------
         Total liabilities                           32,633         25,794
                                              -------------  -------------

Commitments and contingencies

Noncontrolling interest                               4,358              -
                                              -------------  -------------

Shareholders' equity:
  Preferred stock, $.01 par value; authorized
   10,000 shares, issued and outstanding - none           -              -
  Common stock, $.01 par value; authorized
   80,000 shares, issued 45,721 and 45,571
   shares, respectively                                 457            456
  Additional paid-in capital                        242,478        241,555
  Accumulated other comprehensive loss              (15,267)       (14,418)
  Accumulated deficit                               (68,158)       (78,026)
                                              -------------  -------------
                                                    159,510        149,567
  Less cost of treasury stock (2,150 and 585
   shares, respectively)                             (6,120)        (2,294)
                                              -------------  -------------
         Total shareholders' equity                 153,390        147,273
                                              -------------  -------------
         Total liabilities and shareholders'
          equity                              $     190,381  $     173,067
                                              =============  =============





ALLIED HEALTHCARE INTERNATIONAL INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

                                        Year Ended  Year Ended  Year Ended
                                        September   September   September
                                         30, 2010    30, 2009    30, 2008
                                        ----------  ----------  ----------
Cash flows from operating activities:
  Net income                            $   10,056  $   10,303  $    8,786
  Adjustments to reconcile net income
   to net cash provided by operating
   activities:
    Income from discontinued operations          -        (367)          -
    Depreciation and amortization            3,108       2,590       3,231
    Amortization of intangible assets        1,324       1,252       1,634
    Foreign exchange (gain) loss               (43)          7           -
    Increase (decrease) in provision for
     allowance for doubtful accounts            30         360        (167)
    Loss on sale of fixed assets                31          20         166
    Stock based compensation                   636         537         812
    Deferred income taxes                       61         117          88
  Changes in operating assets and
   liabilities, excluding
   the effect of businesses acquired
   and sold:
    Decrease (increase) in accounts
     receivable                                 82      (4,281)      1,579
    (Increase) decrease in prepaid
     expenses and other assets              (1,544)      2,318      (3,488)
    Increase (decrease) in accounts
     payable and other liabilities           2,260       2,867      (3,779)
                                        ----------  ----------  ----------

      Net cash provided by continuing
       operations                           16,001      15,723       8,862
      Net cash used in discontinued
       operations                                -           -        (561)
                                        ----------  ----------  ----------
      Net cash provided by operating
       activities                           16,001      15,723       8,301
                                        ----------  ----------  ----------

Cash flows from investing activities:
  Capital expenditures                      (2,768)     (2,850)     (3,344)
  Acquisition of controlling interest,
   net of cash acquired                     (5,680)          -           -
  Proceeds from sale of business held in
   escrow and designated for debt
   repayment                                     -         116      53,638
  Proceeds from sale of property and
   equipment                                    73           1          50
  Payments on acquisitions payable               -      (1,082)          -
                                        ----------  ----------  ----------

      Net cash (used in) provided by
       investing activities                 (8,375)     (3,815)     50,344
                                        ----------  ----------  ----------

Cash flows from financing activities:
  Repayments of debt and capital lease
   obligations                                (152)          -           -
  Payments under revolving loan, net             -           -     (24,664)
  Borrowings (payments) under invoice
   discounting facility, net                   255           -      (4,458)
  Principal payments on long-term debt           -           -     (23,678)
  Proceeds from sale of interest rate
   swap agreements                               -           -         617
  Treasury shares acquired                  (3,826)          -           -
  Stock options exercised                      288           -           -
                                        ----------  ----------  ----------

      Net cash used in financing
       activities                           (3,435)          -     (52,183)
                                        ----------  ----------  ----------

Effect of exchange rate on cash               (433)     (2,834)       (504)
                                        ----------  ----------  ----------

Increase in cash                             3,758       9,074       5,958

Cash and cash equivalents, beginning of
 year                                       35,273      26,199      20,241
                                        ----------  ----------  ----------

Cash and cash equivalents, end of year  $   39,031  $   35,273  $   26,199
                                        ==========  ==========  ==========

Supplemental cash flow information:
  Cash paid for interest                $       30  $      405  $    1,143
                                        ==========  ==========  ==========

  Cash paid for income taxes, net       $    1,459  $    1,102  $    4,872
                                        ==========  ==========  ==========

Supplemental disclosure of non-cash
 investing and financing activities:
  Capital expenditures included in
   accrued expenses and other long-term
   liabilities                          $      609
                                        ==========

  Details of business acquired in
   purchase transactions:
    Fair value of assets acquired       $   12,319
                                        ==========

    Liabilities assumed or incurred     $    2,715
                                        ==========

    Noncontrolling interest             $    3,888
                                        ==========

    Cash paid for acquisitions          $    5,716
    Cash acquired                               36
                                        ----------

    Net cash paid for acquisitions      $    5,680
                                        ==========





ALLIED HEALTHCARE INTERNATIONAL INC.
HISTORICAL REVENUES AND GROSS PROFIT
(In thousands, except foreign exchange rate)
(Unaudited)


                                             Revenues

                             Q4           Q3           Q2           Q1
                            2010         2010         2010         2010
                        ------------ ------------ ------------ ------------

Homecare                  GBP 39,255   GBP 38,323   GBP 35,860   GBP 35,903
Nursing Homes                  3,048        2,731        2,864        3,261
Hospitals                      3,114        2,933        3,235        3,330
                        ------------ ------------ ------------ ------------
Total                     GBP 45,417   GBP 43,987   GBP 41,959   GBP 42,494
Foreign Exchange rate           1.55         1.49         1.56         1.63
                        ------------ ------------ ------------ ------------
                        $     70,417 $     65,748 $     65,530 $     69,384
                        ============ ============ ============ ============


                                           Gross Profit

                              Q4           Q3           Q2           Q1
                             2010         2010         2010         2010
                        ------------ ------------ ------------ ------------

Homecare                  GBP 12,188   GBP 11,651   GBP 11,083   GBP 11,041
Nursing Homes                  1,002          882          931        1,033
Hospitals                        812          696          755          712
                        ------------ ------------ ------------ ------------
Total                     GBP 14,002   GBP 13,229   GBP 12,769   GBP 12,786
Foreign Exchange rate           1.55         1.49         1.56         1.63
                        ------------ ------------ ------------ ------------
                        $     21,712 $     19,768 $     19,948 $     20,877
                        ============ ============ ============ ============


                                             Revenues

                             Q4           Q3           Q2           Q1
                            2009         2009         2009         2009
                        ------------ ------------ ------------ ------------

Homecare                  GBP 35,763   GBP 34,162   GBP 30,858   GBP 30,620
Nursing Homes                  3,986        3,716        4,159        4,808
Hospitals                      2,956        2,914        3,448        3,612
                        ------------ ------------ ------------ ------------
Total                     GBP 42,705   GBP 40,792   GBP 38,465   GBP 39,040
Foreign Exchange rate           1.64         1.55         1.44         1.58
                        ------------ ------------ ------------ ------------
                        $     69,845 $     63,103 $     55,334 $     61,528
                        ============ ============ ============ ============


                                           Gross Profit

                             Q4           Q3           Q2           Q1
                            2009         2009         2009         2009
                        ------------ ------------ ------------ ------------

Homecare                  GBP 10,951   GBP 10,525    GBP 9,753    GBP 9,487
Nursing Homes                  1,257        1,187        1,298        1,477
Hospitals                        745          679          874          973
                        ------------ ------------ ------------ ------------
Total                     GBP 12,953   GBP 12,391   GBP 11,925   GBP 11,937
Foreign Exchange rate           1.64         1.55         1.44         1.58
                        ------------ ------------ ------------ ------------
                        $     21,196 $     19,173 $     17,166 $     18,813
                        ============ ============ ============ ============

NEW YORK, NY–(Marketwire – December 7, 2010) –   The Global Awards®, honoring the “World’s Best Healthcare Advertising™,” announced its 2010 award winners Monday, December 6th at a cocktail party held at the Eli Klein Gallery in New York. The competition will host two award presentations this year, taking the celebrations globally to New York, USA and Sydney, Australia. This year’s GrandJury® awarded two prestigious Grand Global Awards, one to Taxi Canada, and the second to McCann Healthcare Worldwide Japan, as well as 31 Global Awards and 115 Finalist Certificates. 

The Global Awards presentation in New York began with a cocktail reception and hors d’oeuvres; attendees viewed a print and video showcase of the “World’s Best Healthcare Advertising™.” Global Awards Executive Director Michael Demetriades and Global Awards Advisory Board Chairman & Draft FCB Healthcare Chairman Emeritus Tom Domanico presented the trophies to the 2010 award winners. Mr. Domanico commented on this year’s entries, “Each year I’m more impressed with the quality of the work submitted for judging. It speaks volumes about the talent in the Healthcare industry.”

The GrandJury awarded Taxi, of Toronto Canada, the prestigious Grand Global Award for “Antiquing/Strolling/Reading” for client Viagra, winning in Television Advertisement “Communication to the Consumer/Patient.” The premise of the award-winning commercials — when couples stop having sex, they fill the void with other couple activities that can end up taking over their lives; with the help of Viagra, these couples were able to get back into the bedroom again. 

Taxi’s Chief Creative Officer Steve Mykolyn accepted the award in New York and commented, “It’s great to win a Grand Global Award. This win is doubly great for TAXI and Pfizer because the work being recognized for Viagra had two things going for it; a fantastic insight, plus the power to entertain, even with repeated viewings. Make that three things. The campaign also had a positive impact on sales.”

Creative credits for “Antiquing/Strolling/Reading” include: Darren Clarke, Executive Creative Director; Nathan Montieth, Art Director/Writer; Stefan Wegner, Writer/Art Director; and Eugene Marchio, Agency Producer. In addition to the Grand Global Award, Taxi also received a Global Award for “Antiquing” for client Viagra.

McCann Healthcare Worldwide Japan was awarded the coveted Grand Global Award for “It’s Easy” for client Saizen (easy pod) Merck Serono, winning in New Product Launch “Communication to the Healthcare Professional.” The award-winning video illustrates a simple delivery device to administer human growth hormone and features a young girl dancing as she evolves into a woman. Creative credits include: Hajime Nakazawa, Creative Director & Copywriter; Yasutoshi Yamamoto, (Aoyama Creative Studio) Agency Producer; as well as Dee Drive’s Director Wataru Takeishi and Producer Yuko Niwa.

The United States was awarded 10 Global Awards: American Academy of Orthopaedic Surgeons for “Wounded in Action: An Art Exhibition of Orthopaedic Advancements”; Blue Shield of California for “Shield Helps”; CAHG for “Takeda Unbranded Convention Booth” for client Takeda Pharmaceuticals; Crowley Webb and Associates for “Risk Files Poster Campaign” for client Praxis; DeSantis Breindel for “Improving the Health and Health Care of All Americans: A Film About the Robert Wood Johnson Foundation” for client The Robert Wood Johnson Foundation; GSW Worldwide for “When the Body Attacks Itself Campaign” and “When the Body Attacks Itself Photography” for client Kalbitor; PALIO and ZEMOGA for “The Health Tweeder” for client The Health Tweeder. And Seiden was awarded two Global Awards, one for “The Book of Brave” for client Shire Pharmaceuticals, and a second for “Working Harder” for client Visiting Nurse Service of New York.

The 2010 Global Awards GrandJury recognized winners from 17 countries around the world. The United Kingdom received 5 Global Awards: Langland took the lead and was awarded 4 Global Awards receiving trophies for “Kogenate Self Infusion Mailer” for client Kogenate; “Real Danger” for client Pfizer; “Stalevo Dose Tool” for client Stalevo; and “Let’s Work” for Boehringer Ingelheim Oncology. In addition, Random42 Medical Animation was awarded the Global Award for “A Biotechnology Pioneer” for client Amgen Oncology; and RTC Europe was honored for “Siemens Global POS System” for Siemens Audiologische Technik GmbH.

In addition to Taxi Canada receiving both the Grand Global Award and Global Award for client Viagra, LXB Canada was also awarded a Global Award for “Sydney” for client Synagis.

Belgium, Germany, India, Italy, Spain, Sweden, and Switzerland each were honored with one Global Award. Norvell Jefferson Productions Belgium was honored with the Global Award for “The Making of Protein Therapies” for client Genzyme; Young & Rubicam GmbH Germany was awarded the Global Award for “Stairs” for BFF (Counseling for sexually abused or threatened women); McCann Healthcare Mumbai, India was awarded the Global Award for “Marriage/Study/Drive/Fly/Pleasure/Mother” for client Epilex Chromo; Sudler & Hennessey Italy garnered a Global Award for “From Science to Life” for client MIO, i.e. Milano International Oncology; HC BCN Spain was honored with a Global Award for “Bubbles” for client Aerored; Animech Sweden was acknowledged for “The Unknown Mr. Parkinson” for client EPDA; and Euro RSCG Zürich, Switzerland was recognized for “Quick Sex” for Swiss Health Department.

A Global Awards ceremony will also be held on Wednesday, December 8^th in Sydney, Australia presented by The Global Awards and Bravo!, a group of Australian healthcare professionals, with representation from healthcare agencies, and the Communications Council of Australia. The evening will begin with a cocktail reception and canapés at Sydney’s Simmer on the Bay, located on historic Walsh Bay. Award winners and their guests will view a showcase of 2010’s winning work, followed by an award ceremony presented by International Awards Group President, Michael O’Rourke. Award Winners will be posted at www.theglobalawards.com following the event.

Judging sessions for this year’s Global Awards were hosted by the following prominent international agencies: McCann Erickson Sydney, Australia; Ogilvy Healthworld London, England; Pharmacom Barcelona, Spain; Topin & Associates Chicago, USA; Trademark DM Melbourne, Australia; and at The Global Awards headquarters in New York, USA. 

Now in its 16^th year, The Global Awards receives entries from healthcare corporations, hospitals, advertising agencies, production companies, and design studios that produce communications for medical, pharmaceutical, and healthcare related products. The Global Awards Advisory Board and GrandJury are comprised of a panel of prominent international industry experts, representing the top creative minds in the field of healthcare advertising. 

All winning entries are featured at: www.theglobalawards.com, and are promoted by our network of representatives in 75 countries around the world.

All press inquiries are welcome and should be directed to Gayle Mandel: [email protected]. Phone 212 643 4800.

About the Global Awards
Now in their sixteenth year, The Global Awards are recognized as the only awards dedicated to excellence in healthcare communications on an international basis. 

International Awards Group International Awards Group (IAG) organizes advertising and programming competitions for the following brands: AME Awards® for the World’s Most Effective Advertising™; Midas Awards® for the World’s Best Work in Financial Marketing & Advertising™; The Global Awards® for the World’s Best Healthcare Advertising™; New York Festivals®; World’s Best Advertising™; World’s Best Radio Programs™ and World’s Best Television & Films™. Entries to each of the competitions are judged around the world by panels of peers in their respective industries. Founded in 1957, IAG and their brands now have representation in 75 countries. For more information, go to www.InternationalAwardsGroup.com.

Click here to see all recent news from this company

SOMERSET, NJ–(Marketwire – December 6, 2010) – TeamStaff, Inc. (NASDAQ: TSTF), a leading logistics and healthcare services provider to the Federal Government and Department of Defense announced today that its President and Chief Executive Officer, Mr. Zach Parker, will deliver a presentation to investors at the Third Annual LD MICRO Conference on Thursday, December 9, 2010 at 3:00pm PST. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California. A copy of the presentation will be made available in the Investor Relations section of the TeamStaff website (http://teamstaff.com/investor-relations) and also furnished as an exhibit to a Current Report on Form 8-K to be filed by the Company with the SEC.

“I’m pleased to present the TeamStaff story at this year’s LD MICRO investor conference as we believe we have laid the proper foundation to facilitate growth especially into adjacent markets with new customers, like the DoD. I am thankful to participate in this investor conference and I am looking forward to meeting with attendees who specifically have an interest in microcap companies,” said Zach Parker, Chief Executive Officer of TeamStaff.

“We are very pleased to have TeamStaff present at our third annual event,” said Chris Lahiji, President of LD MICRO. “I take pride in having an event that showcases companies of all sizes, in all industries. TeamStaff is a great addition to our roster this year.”

For more information on the conference or to register for the event, please visit http://www.ldmicro.com or call (408) 457-1042.

About TeamStaff, Inc.

TeamStaff serves clients and their employees throughout the United States as a full-service provider of logistics and healthcare support services. TeamStaff specializes in providing high quality healthcare, logistics, and technical services to Federal agencies and the Department of Defense. For more information, visit the TeamStaff corporate web site at www.teamstaff.com or the TeamStaff Government Solutions web site at www.teamstaffgs.com.

This press release contains “forward-looking statements” as defined by the federal securities laws and involve numerous risks and uncertainties. TeamStaff’s actual results could differ materially from those described in such forward-looking statements as a result of such risks and uncertainties. For a discussion of such risks and uncertainties, see “Risk Factors” in the Company’s periodic reports filed with the U.S. Securities Exchange Commission. The information in this release should be considered accurate only as of the date of the release. 

VANCOUVER, BC–(Marketwire – December 6, 2010) – Digital Payment Technologies (http://www.digitalpaytech.com) (DPT), a leading supplier of parking technology and solutions, today announced that the city of Houston, Texas, will roll out an additional 250 of the company’s LUKE pay stations, marking a significant expansion of an already successful deployment program. On December 8, DPT will host a webinar with Houston’s director of parking management, Liliana Rambo, CAPP, who will share insights gained from her experience planning and implementing a large-scale parking technology transition that has been favorably met by officials and the public in the fourth largest city in the U.S.

The 250 new LUKE pay stations will be configured similarly to those in the original deployment that began in 2006. They will connect to the city’s back-end parking management systems via Wi-Fi, will accept coins, bills and credit cards, and in the future will be able to accept payment by cellular phone. This brings the total number of DPT pay stations in Houston to 1,000, and marks yet another milestone in a tremendously successful program.

“DPT pay stations enable Houston’s parking management division to meet its objectives of delivering superior service to consumers and optimizing operational efficiency,” said Rambo. “In these difficult economic times, the operational efficiency and increased revenue made possible by these advanced parking systems have enabled the city to continue to fund many important municipal programs.”

Houston’s project was initiated to replace outdated single- and double-head parking meters, improve the parking experience for the public, reduce traffic congestion, increase parking turnover and improve the bottom line. By implementing a comprehensive rollout plan that included a variety of communications strategies with key stakeholders throughout the process, Houston’s Parking Management Division has secured some impressive results, including:

• 80 percent revenue increase without an increase in parking rates.
• 33 percent productivity improvement for meter operations staff.
• 1,000 more paid citations per month, equal to $58,000 in revenues, due to citations being upheld in adjudication. The new technology leaves less room to dispute tickets.

DPT’s December 8^th webinar will provide additional details and best practices from this $15.4 million advanced parking project that will be useful to municipal, county and state government departments, as well as private parking operators responsible for parking and enforcement. Free registration is available at: http://event.on24.com/r.htm?e=265402&s=1&k=8C1A49910D44B77405A4E608E0F0843D&partnerref=dpt1

“The City of Houston’s use of multi-space pay stations is a testament to the positive impact that smart parking initiatives can have on a city,” said Alan Menezes, vice president of product management and marketing with Digital Payment Technologies. “There is a great opportunity for cities that still rely upon single-head parking meters to institute a similar parking plan and reap the benefits. Our customizable pay stations, back-end services and support and seamless integration with leading industry partners put DPT in the unique position of offering a complete parking solution composed of best-in-class components. Furthermore, DPT has significant experience helping large and small municipalities ensure a smooth transition as they embrace multi-space parking.”

Houston/DPT Webinar Details:
Date: Wednesday, December 8, 2010
Time: 2:00 p.m. EST / 11:00 a.m. PST
Cost: Free
Register: http://event.on24.com/r.htm?e=265402&s=1&k=8C1A49910D44B77405A4E608E0F0843D&partnerref=dpt1 

About Digital Payment Technologies
Digital Payment Technologies (DPT) is an innovative leader in the design, manufacture, and distribution of electronic parking meters, management software, and online services for the parking industry. DPT products provide complete financial tracking, control, and reporting on parking revenue collected by cities, municipalities, universities, parking management companies, private operators, and national parks, from customer payment through to bank deposit. In 2007, DPT was named Emerging Company of the Year by the British Columbia Technology Industry Association, and has been included on multiple Deloitte Technology Fast 50 and Fast 500 lists as one of the fastest growing high technology companies in North America. For more information visit: http://www.digitalpaytech.com

Click here to see all recent news from this company

BURLINGTON, VT–(Marketwire – December 3, 2010) – Marathon Health today announced that C&S Wholesale Grocers, the largest grocery wholesaler in the country, will open an onsite healthcare facility at their headquarters in Keene, N.H. on December 6, 2010.

The C&S Healthy Living Wellness Center, which will be managed by Marathon Health, will serve employees and their families, including dependents over the age of six, within the Brattleboro, VT and Keene, NH area. Available services include acute and primary care, wellness and health promotion, health coaching, disease management, medication dispensing, and the Marathon eHealth Portal technology to support the delivery of care and coaching. The Center staff will include two nurse practitioners, a registered nurse and a medical assistant.

“Marathon Health shares our philosophy about healthcare responsibility and has the tools and programs to help improve the overall health of our workforce,” said Richard Cohen, C&S Chairman and CEO. The worksite healthcare initiative will be offered as part of the company’s Total Rewards health programs that encourage people to be active participants in their own health and healthcare.

“What is most important at Marathon Health is how we inspire people to understand and care about their health — it is the foundation of what we do. We are excited to help C&S enhance the culture of health and responsibility they have established,” said Jerry Ford, Marathon Health CEO.

About C&S Wholesale Grocers

C&S Wholesale Grocers of Keene, NH, is the largest food wholesaler and according to Forbes magazine, the 10th largest privately held company in the United States. The company distributes food to supermarkets, retail stores and military bases across the country.

Currently, C&S serves about 3,900 stores from more than 50 locations in 11 states. Among our customers are many of America’s best known companies, including Stop & Shop, Giant of Carlisle, Giant of Landover, Shaw’s, Great Atlantic & Pacific Tea Co. (A&P), Ralphs, Safeway and Target.

About Marathon Health

Marathon Health of Colchester, VT, offers a proven solution for helping employers reduce the total cost of healthcare. The Marathon Health approach integrates the best practices of onsite primary care, health assessment with risk identification, coaching and advocacy, and disease management for high cost chronic conditions. Marathon Health supports its unique model with an eHealth Portal delivering medical content, interactive diet and fitness tools, a personal health record, and an electronic medical record to manage care. For more information, please visit www.marathon-health.com.

SYDNEY, AUSTRALIA–(Marketwire – December 2, 2010) –  Sunshine Heart Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced the successful completion of its non-renounceable rights issue to existing shareholders, raising a total of A$9.5 million.

88 per cent of entitlements were taken up under the rights issue including the shortfall facility, leaving 44,761,462 shares unsubscribed.

The rights issue follows the Company’s recent successful placement to US institutional investors raising A$3.7 million (announced 16 September 2010), bringing the total proceeds to A$13.2 million before deducting fees and expenses.

Majority Australian shareholders, GBS Venture Partners and CM Capital, both continued their strong support for the Company, taking up their full entitlements and also some of the shortfall, for an aggregate amount of $6.6 million

Sunshine Heart Chief Executive Officer Dave Rosa said, “We are delighted to have such strong support from existing shareholders and welcome new US institutional investors during this exciting and pivotal period for Sunshine Heart.”

The capital will be used to fund the key activities of the Company. The most important of these is to advance the regulatory trials in the US by completing the current 20-patient feasibility trial and six-month patient follow up, then preparing the application for the larger FDA pivotal trial which is the precursor for marketing approval in the USA. The Company expects to have approval for this trial and to start implants during 2011.

The money will also be used to apply for CE Mark approval in 2011 which will allow the C-Pulse heart assist device to be marketed in Europe and parts of Asia.

The Company will continue its development of a new, single unit C-Pulse driver as well as introducing product changes to facilitate minimally invasive implant procedures.

The successful US placement was managed by specialist healthcare investment firm Summer Street Research Partners Inc. The non-renounceable rights issue was managed by RBS Morgans in Australia.

About Sunshine Heart Inc.
Sunshine Heart Inc. (ASX: SHC), a global medical device company focused on innovative technologies for the treatment of moderate heart failure, is commercializing the C-Pulse® Heart Assist System, a minimally invasive, implantable, non-blood contacting, heart assist therapy for the treatment of moderate heart failure. The C-Pulse System is designed to relieve the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart’s pumping load. The Company has received approval from the US Food and Drug Administration (FDA) to conduct a 20-patient U.S. feasibility clinical trial with the C-Pulse System and the study has achieved eighty percent enrolment as of November 2010. Sunshine Heart, Inc. is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia.

About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System uses proprietary balloon counterpulsation technology to increase the amount of blood pumped by the heart and to reduce the workload on the heart. The C-Pulse System is implanted in the patient’s chest through a sternotomy or through a small incision when performed as a minimally invasively procedure. During the procedure, there is no need to place the patient on a heart-lung machine as the patient’s heart remains beating continuously. 

Once implanted, the C-Pulse cuff is positioned on the outside of the patient’s ascending aorta above the aortic valve. An ECG sense lead is then attached to the heart to determine timing for cuff inflation and deflation in synchronization with the heartbeat. The C-Pulse cuff and lead are connected to a single line that is run through the abdomen to connect to a power driver outside the body. Because the C-Pulse System remains outside the blood system, there is potentially less risk of blood clots and stroke in comparison to other mechanical devices, such as left ventricle assist devices (LVADs).

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company’s filings with the Australian Securities Exchange. The shares of Sunshine Heart have not been registered under the Securities Act of 1933 (US Securities Act) and may not be offered, sold or delivered in the United States, or to, or for the account or benefit of, any US Person, as such term is defined in Regulation S of the US Securities Act. In addition, hedging transactions with regard to the shares may not be conducted unless in accordance with the US Securities Act.

Click here to see all recent news from this company

MOUNTAINSIDE, NJ–(Marketwire – December 2, 2010) – Proteonomix, Inc. (OTCBB: PROT) (“Proteonomix” or the “Company”) announced today that it has updated its corporate website (http://www.proteonomix.com/) to reflect the dynamic growth and investment opportunity that exists today.

Michael Cohen, CEO stated: “The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancing regenerative stem cell therapies, services, and products through a combination of first to market technologies and innovative clinical trial strategies. Stem cell treatment provides much promise for the treatment of diseases previously regarded as incurable. Through years of research and development, Proteonomix has developed breakthroughs in stem cell therapies for disease and injury, identification biomarkers and reproductive cell/tissue laboratory services.”

“Proteonomix is now actively negotiating strategic partnerships and opportunities for its breakthrough products and technology. We are currently in negotiations to joint venture our patents and intellectual properties with various entities and will be updating the investment community as these milestones are completed,” concluded Mr. Cohen.

About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development of therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements: Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. More specifically, the investment may never occur negating the agreement, product performance and/or side effects may necessitate termination of the joint venture, the implementation of the agreement may not succeed and inadequate or no business may develop causing the failure of the joint venture and there are inherent risks in foreign operations, particularly those in the Mideast. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Click here to see all recent news from this company

BURNS, TN–(Marketwire – December 2, 2010) – New Life Lodge drug and alcohol addiction treatment center, in conjunction with parent company CRC Health Group, the nation’s largest provider of behavioral health and addiction treatment services, today announced the completion of the multi-facility acquisition of Recovery Living Services (RLS) in Tennessee. 

“We are pleased to acquire RLS, which has been providing high quality addiction treatment services for over five years, and to expand the outreach and breadth of services of New Life Lodge,” said Jerry Rhodes, President of the Recovery Division of CRC Health Group. “There are a number of Tennesseans who are dependent on drugs or alcohol and are in desperate need of quality recovery services. We want to help these individuals in their pursuit to reclaim their lives.”

According to the Substance Abuse and Mental Health Services Administration’s (SAMHSA) most recent National Survey on Drug Use and Health, approximately 444,000 (9%) of Tennessee citizens ages 12 or older reported past month use of an illicit drug, with 151,000 citizens reporting dependence or abuse of an illicit drug within the past year. Yet in 2008 (most recent year of data), there were only 9,806 admissions to drug/alcohol treatment centers in Tennessee. Approximately 129,000 Tennessee citizens reported needing but not receiving treatment for illicit drug use.

RLS provides substance abuse treatment for adults and adolescents as well as in-home behavioral health counseling services for at-risk youth. The acquired facilities — located in Downtown Knoxville, West Knoxville, Cookeville, Jamestown and Jacksboro — will continue to provide intensive outpatient program (IOP) services, outpatient opiate (Suboxone-based) detoxification services, and intensive in-home services. In addition, plans are underway to open two additional facilities in Chattanooga and Memphis.

Rebecca Gaskin, LCSW, CAC, MSW, MBA and current Executive Director of New Life Lodge, will oversee the additional facilities. Current CEO of Recovery Living Services, George Massengill, will stay on with CRC Health Group.

“I am very excited to have Recovery Living Services join the New Life Lodge family to serve persons struggling with substance abuse disorders throughout the state of Tennessee,” said Gaskin. “New Life Lodge is committed to providing high quality, effective treatment and RLS has demonstrated the same commitment in outpatient treatment settings throughout the eastern Tennessee area. This partnership will allow New Life Lodge to offer a seamless array of treatment opportunities for individuals to optimize their residential treatment experience and support them as they integrate back into their home environments.”

Gaskin added, “We hope to make our services widely available to those struggling with addiction by expanding our outpatient facilities across the state.”

New Life Lodge has been providing rehabilitation and treatment services for adults and adolescents struggling with alcohol and drug dependency for over 25 years. The treatment center acknowledges that addiction affects the entire family and therefore embraces the family as well as the individual to provide personalized treatment services. Under the supervision of licensed professionals, New Life Lodge has built a nationally recognized reputation and established long-standing relationships within the medical and mental health communities. The program is licensed by the Tennessee Department of Health and the Tennessee Department of Healthcare Facilities, and is CARF-accredited. For more information, visit www.newlifelodge.com.

New Life Lodge is a member of CRC Health Group, the most comprehensive network of specialized behavioral care services in the nation. CRC offers the largest array of personalized treatment options, allowing individuals, families and professionals to choose the most appropriate treatment setting for their behavioral, addiction, weight management and therapeutic education needs. CRC is committed to making its services widely and easily available, while maintaining a passion for delivering advanced treatment. Since 1995, CRC has been helping individuals and families reclaim and enrich their lives.
For more information, visit www.crchealth.com or call (877) 637-6237.

RYE BROOK, NY–(Marketwire – December 2, 2010) – CBLPath today announced that it is now officially part of Sonic Healthcare Limited’s federation of laboratories.

CBLPath will work closely with Sonic’s clinical laboratory divisions to cross sell services to their respective referrer bases. Significant revenue synergies are expected to be realized from the cross sell opportunities in FY2012 and following years. In addition, there are a number of cost synergies which Sonic can offer CBLPath, particularly in the areas of logistics, purchasing and billing.

CBLPath has been operating under the direction of the Office of the CEO comprised of David W. Bryant, President and Chairman of the Board; Dr. Carlos D. Urmacher, Chief Medical Officer; and Joe Sinicropi, Chief Operating Officer. At this time, the Office of the CEO will be disbanded and Mr. Bryant will assume the role of CBLPath’s Chief Executive Officer. Dr. Urmacher will continue in his role as Chief Medical Officer and Mr. Sinicropi in his role as Chief Operating Officer.

The company will continue to operate under the CBLPath name.

About CBLPath
CBLPath is a national specialty lab offering a full convergence of anatomic, molecular and digital pathology services. The company provides a one-stop solution for comprehensive sub-specialized diagnostics, and timely, accurate, patient-centered disease management guidance. Through its Best Practice™ Partnership Program, CBLPath partners with pathologists to help them grow their practices, while giving them the ability to stay independent and “keep medicine local.” The company also provides sub-specialty physicians access to comprehensive, high-quality testing in their local market. Founded in 1988, CBLPath established a reputation for providing timely, highly accurate diagnoses along with extraordinary customer service and a true patient-centered commitment. For more about the company, please visit www.CBLPath.com.

About Sonic Healthcare Limited
Sonic Healthcare is one of the world’s largest medical diagnostics companies, providing laboratory and radiology services to medical practitioners, hospitals, community health services, and their collective patients. Sonic Healthcare Limited is the parent company of the many operating companies around the world comprising the Sonic Healthcare group. It is a public company, listed on the Australian Securities Exchange (ASX), where it is classified as one of Australia’s “Top 100” companies. Sonic Healthcare has its head office at Macquarie Park in Sydney, Australia, in the same building as the main Douglass Hanly Moir Pathology laboratory. In the medical arena, their success is based on the fact that Sonic Healthcare companies are recognized as quality diagnostic practices that have remained true to the ethical principles of the medical profession. For more about the company, please visit www.sonichealthcare.com.

AUSTIN, TX–(Marketwire – November 30, 2010) – ProAssurance Corporation (NYSE: PRA) today completed its previously announced acquisition of American Physicians Service Group, Inc. (“APS”) (NASDAQ: AMPH). As a result of the merger, APS is now a wholly-owned subsidiary of ProAssurance.

The Chairman and Chief Executive Officer of APS, Ken Shifrin, said, “We’ve found the ideal partner to carry on the physician-focused traditions of APS. We know that ProAssurance will continue to serve our 6,800 insureds with the individual attention that is a part of our mutual corporate cultures. The last decade has resulted in a spectacular 36% average annual increase in APS’ stock price, from $1.50 to $32.50, and I want to thank our shareholders for their trust and for the opportunity to lead the company during this exciting time. I also want to say what an honor it has been to work with the board of directors and employees of APS and to thank them for their loyalty and dedication.”

“We are excited about the opportunities this transaction creates for us,” said ProAssurance’s Chairman and Chief Executive Officer, W. Stancil Starnes. “Not only does it give us significant market presence as the second largest writer of medical professional liability (MPL) insurance in Texas, it also enhances our presence in Oklahoma and Arkansas. We expect to leverage the skill and dedication of APS’ employees to deliver an unmatched level of service and financial strength to policyholders in these three key states. Additionally, we believe our shareholders will see benefits as well, as we expect to grow profitably during a challenging time in our business.”

Under the terms of the merger, each share of APS stock was redeemed for $32.50 in cash. Shareholders whose stock is held by a broker or in direct registration will be paid automatically. Those APS shareholders with stock certificates will receive instructions by mail for surrendering their shares in order to receive payment. Shareholders with questions about the share conversion process may contact American Stock Transfer & Trust at (877) 248-6417.

As a result of this transaction, APS’ common stock will cease to trade on the Nasdaq Stock Market prior to the open of business on December 1, 2010, and will thereafter be delisted.

About APS

APS is an insurance holding company with subsidiaries that provide medical malpractice insurance for physicians and other healthcare providers. APS is headquartered in Austin, Texas. Further information about the company is available on the Internet at www.amph.com.

WESTPORT, CT–(Marketwire – November 29, 2010) – African community groups are transforming the future for orphans and other children affected by HIV and AIDS thanks to U.S.-funded programs, Save the Children said.

“The United States is doing much more than providing lifesaving drug treatment when it comes to helping people around the world battle the AIDS crisis and it must continue to do so,” said Charles MacCormack, President and CEO of Save the Children. “One of the most remarkable changes is the creation of African community networks dedicated to supporting orphans and other children affected by HIV and AIDS.”

“It’s amazing how care and support can replace stigma and isolation when local groups are empowered to mobilize around children who have been orphaned and left vulnerable by HIV and AIDS,” MacCormack said.

More than 17 million children have lost one or both parents to AIDS. Many millions more children have reduced opportunities in life because HIV and AIDS have struck their families and communities. Most of these children are in Africa.

The United States President’s Emergency Plan for AIDS Relief (PEPFAR) has funded programs offering care and support to more than 3.6 million orphans and vulnerable children in Africa. Save the Children has led several of these large programs in Mozambique, Uganda, and Ethiopia and has put special emphasis on empowering local community groups to care for affected children. The result is sustainable change for children.

For World AIDS Day (Dec. 1), Save the Children has released a new multimedia video highlighting new hope for orphans and other children affected by AIDS in Ethiopia, where 530,000 children have benefited from U.S.-funded programs. 

“One of the most interesting changes involves Ethiopia neighborhood associations that originally formed to help poor families cover funeral expenses,” MacCormack said. “Today these groups have transformed to offer new hope to the living. They are helping children get an education, enough to eat, a place to live, and, perhaps most importantly, a renewed sense of community and loving support that they had lost to AIDS.”

See the video and learn how you can help support children affected by HIV and AIDS here:
www.savethechildren.org/worldAIDSday2010

Save the Children is the leading, independent organization that creates lasting change for children in need in the United States and 120 countries around the world.

FOSTER CITY, CA–(Marketwire – November 27, 2010) – TeraRecon, Inc. (www.terarecon.com), a global leader in advanced visualization and decision support solutions, has received the North American Growth Leadership of the Year Award in the category of Advanced Visualization and Clinical Applications by the respected independent research firm Frost and Sullivan. This award represents the sixth time in the past 10 years that TeraRecon, Inc. has been recognized with an award from Frost and Sullivan. It is the second time in 2010, following the European Company of the Year Award in the category of Medical Imaging, Advanced Visualization Applications. The full text of the new award can be reviewed on the company’s website at www.terarecon.com/fs2010-2.pdf

The Award is issued contemporaneously with the release of the new Frost and Sullivan market research report on the North American advanced visualization market, and is derived from independent and objective research performed by the Frost and Sullivan team, which was not commissioned or funded by TeraRecon. The research was based on two independent primary research efforts conducted during the last year by Frost & Sullivan researchers, each focused on decision makers for advanced visualization in the United States.

Quoting from the text of the Frost and Sullivan award, “In more than one aspect, TeraRecon has become the leading independent vendor in the North American advanced visualization industry today.” The award noted that TeraRecon is “…capturing a higher market share than all other vendors within its tier of competition” and also recognized the company’s focus on the role and potential of advanced visualization in the healthcare enterprise: “Indeed, TeraRecon’s solutions achieve the highest ratings with regard to their remote access and integration capabilities, making TeraRecon the market leader for delivering advanced visualization enterprise-wide.”

The research also revealed that TeraRecon is perceived as the vendor offering the most advanced technology and the highest performance, that TeraRecon obtained the highest ratings for customer satisfaction, and that the surveyed respondents rated TeraRecon’s solution with the highest ratings for ease of use.

Frost and Sullivan made particular note of iNtuition™ CLOUD, stating “The cloud-based solution launched recently by TeraRecon is yet another illustration of the company’s edge with technology and its ability to react swiftly to emerging industry trends and customer needs.”

Furthermore, the value of the company’s investment in research and development of clinical applications was acknowledged with the observation that “TeraRecon achieved the highest ratings among independent vendors not only from a technology standpoint, but also from a clinical standpoint.”

TeraRecon President & CEO Robert Taylor, Ph.D. commented on the award, “We are truly honored to have received a sixth Frost and Sullivan award — the second within a single year, now recognizing the company’s achievements in the North American market, following up on the recognition we received from Frost and Sullivan earlier in the year relating to our innovative business strategy in Europe. This independent research by Frost and Sullivan objectively proves what we have always strived for relating to our customers’ appreciation of our products’ performance, our customer service, our clinical excellence, and our commitment to enterprise workflow and integration with other informatics systems. The accompanying report also highlights that TeraRecon’s enjoys the highest attachment and integration rate to PACS systems deployed in the North American market, as further evidence of the company’s commitment to a radiologist-centric workflow.”

Dr Taylor continued, “TeraRecon is more committed than ever to innovation and technological and clinical excellence. We are defining new boundaries for advanced visualization every day, as our new iNtuition CLOUD offering gains more and more registered users and the clinical capabilities of iNtuition expands rapidly. We believe that the future of medical imaging will inevitably consist of a combination of on-site software, cloud-based hosting, and meaningful integration with other enterprise healthcare informatics systems, and we embrace this challenge with the greatest enthusiasm and commitment.”

Free evaluation accounts for iNtuition CLOUD can be obtained at terarecon.com/cloud.

About TeraRecon (www.terarecon.com)
TeraRecon is a global leader in advanced image processing, decision support and 3D visualization techniques. The company’s solutions provide advanced imaging support for medical and other visualization applications based on its unique and patented image processing technologies. A six-time winner of Frost and Sullivan awards, the company has developed a leading portfolio of products that advance the performance, quality, functionality, and integration of image processing and 3D visualization systems since its founding in 1997. TeraRecon is a privately held company with headquarters in Foster City, California, USA, European headquarters in Frankfurt, Germany, and branch offices in Concord, Massachusetts, USA and Tokyo, Japan.

About Frost & Sullivan:
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com

iNtuition™ is a trademark of TeraRecon, Inc.

LAS VEGAS, NV–(Marketwire – November 26, 2010) – Fresh Start (OTCBB: CEYY) announces it appointed Dr. Jorge Andres as CEO and Director of the company.

Effective November 22, 2010, Michael Cetrone resigned as President and Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and as a member of the Board of Directors of Fresh Start Private Management, Inc. (the “Company”).

Concurrent with Mr. Cetrone’s resignation, Dr. Jorge Adrade, was appointed Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer. Dr. Andrade was already a member of the Board of Directors of the Company.

Dr. Jorge Andrade Jr. is founder, CEO and President of West Coast Consulting Inc. since 2004. Dr. Andrade is a licensed Doctor of Dental Surgery and National Dental Board Certified since 1998. One of Dr. Andrade’s current positions is Senior Program Co-coordinator for the Western Division of Colgate Palmolive “Bright Smiles Bright Futures Dental Program.” Dr. Andrade is a Licensed Medical Interpreter, a licensed Doctor of Dental Surgery since 1995, and co-founder of TM Cube Medical LLC. Dr. Andrade has exceptional knowledge of starting, building and managing small businesses.

Effective November 22, 2010 the Board of Directors appoints Neil Muller as President.

Neil Muller is one of the world’s leaders in alcohol treatment and recovery and the architect of the Fresh Start Private Program. Mr. Muller has treated over 5,000 patients worldwide and will now focus his efforts on directing the clinics in America to cure the 18 million alcoholics across the country.

About Fresh Start Private™

Fresh Start Private is a company on the leading edge for the treatment of alcohol addiction. The Company’s founder has treated over 5,000 patients. Fresh Start is the only alcohol treatment program in the world to offer a single-administration, long acting, Naltrexone implant™. The non-invasive Naltrexone implant is placed just under the skin in the patient’s abdominal area. The procedure takes about 20 minutes and in nearly every instance patients are released the same day.

For more information, visit www.freshstartprivate.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission.